BofA top picks in biotech as sector heading for recovery in 2026 Jan 7, 2026 09:00PM
Immatics (IMTX) PT Raised to $17 at Leerink Partners Dec 4, 2025 07:20AM
Immatics (IMTX) PT Raised to $19 at Guggenheim Nov 18, 2025 06:30AM
Immatics (IMTX) PT Raised to $14 at BofA Securities Nov 17, 2025 11:36AM
Immatics (IMTX) PT Raised to $24 at Jefferies Nov 13, 2025 04:30AM


Oct 8, 2025 02:54PM Immatics (IMTX) spreader of 8500 contracts of January 5 and 15 calls
Aug 18, 2025 10:53AM Mizuho on Immatics (IMTX): 'Multiple Catalysts on the Horizon; Maintain OP Rating on this PRAME Therapy Leader'
Jun 2, 2025 06:47AM Cantor Fitzgerald Reiterates Overweight Rating on Immatics (IMTX)
May 28, 2025 01:46AM Deutsche Bank Starts Immatics (IMTX) at Buy
Apr 1, 2025 07:14AM Cantor Fitzgerald Reiterates Overweight Rating on Immatics (IMTX)
Dec 16, 2024 05:47AM Mizuho on Immatics (IMTX): 'BMS Cell Therapy Collaboration Discontinued, but No Material Impact; Stock Attractive Here'
Dec 12, 2024 01:17PM Clear Street Starts Immatics (IMTX) at Buy
Nov 18, 2024 04:49PM Immatics (IMTX) PT Lowered to $15 at BofA Securities
Oct 10, 2024 07:32AM Immatics (IMTX) Announces Proposed $150 Million Public Offering
Oct 7, 2024 04:18AM Piper Sandler Starts Immatics (IMTX) at Overweight
Sep 19, 2024 06:55AM Mizuho Reiterates Outperform Rating on Immatics (IMTX)
Sep 13, 2024 06:52AM Mizuho Reiterates Outperform Rating on Immatics (IMTX)
Jul 31, 2024 07:01AM Immatics (IMTX) Appoints Alise Reicin to its Board